Aurobindo Pharma arm Curateq Biologics incorporates new wholly owned subsidiary in Netherlands
Hyderabad: Aurobindo Pharma has announced that Curateq Biologics Private Limited, a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary in the Netherlands by the name of CuraTeQ Biologics B.V.
The move is aimed at expanding the company's Biopharma Products business in Europe.
According to the disclosure, CuraTeQ Biologics B.V. was incorporated on May 28, 2025.
"Initial subscription to the share capital of EURO 10,000 divided into 10000 shares with a nominal value of EURO 1.00 each," the company said in a BSE filing.
No government or regulatory approvals were required for the incorporation.
Medical Dialogues had earlier reported that CuraTeQ Biologics s.r.o., had received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation of Dazublys (150 mg powder for concentrate for solution for infusion), its trastuzumab biosimilar, for the treatment of HER2-positive metastatic and early breast cancers.
CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Limited, is a global biopharmaceutical company headquartered in Hyderabad, India. The company is focused on developing biosimilars for the treatment of various cancers and autoimmune diseases. CuraTeQ's pipeline consists of fourteen biosimilars, primarily targeting the immunology and oncology segments. It has end-to-end capabilities in producing a full range of products from bulk drug substance to fill-finish and packaged drug products.
